BeiGene
2025.06.17
09:40
Takeda Pharmaceutical China President Shan Guohong to join BeiGene
According to several sources, Shan Guohong will join BeiGene. Shan Guohong is currently the global senior vice president of Takeda Pharmaceuticals and the president of Takeda Pharmaceuticals China, and is about to leave. Shan Guohong is expected to replace Yin Min, who is under investigation by regulatory authorities, as the chief business officer of BeiGene Greater China, but Shan Guohong's job responsibilities are different from Yin Min's. The specific time when Shan Guohong will join BeiGene has not yet been confirmed, and BeiGene has not commented on Yicai's inquiries.
2025.06.12
21:49
BeiGene's US stocks rose nearly 7%
BeiGene's U.S. stocks rose nearly 7%. The FDA's official website showed that BeiGene's Zebutinib tablets were approved for marketing.
14:46
The concept of innovative drugs in A-shares continued to be active. Hisun Pharmaceuticals hit the daily limit in the late trading, Osaikang hit the daily limit before that, Shutaishen and Ruizhi Pharmaceutical rose by more than 10%, Qianhong Pharmaceutical, BeiGene, and Changchun High-Tech rose by more than 5%.
14:44
Innovative drug concepts continue to be active; Hisun Pharmaceutical and Aosaikang hit their daily limit
The concept of innovative drugs continued to be active, with Hisun and Osaikang hitting their daily limit, Shutaishen and Ruizhi Pharmaceutical rising by more than 10%, Qianhong Pharmaceutical, BeiGene, and Changchun High-Tech rising by more than 5%.
13:20
Hong Kong-listed biopharmaceutical stocks strengthened again in the afternoon, with Rongchang Biopharma (09995.HK) rising more than 20%, Zai Lab (09688.HK) rising more than 10%, Junshi Biosciences (01877.HK) and BeiGene (06160.HK) rising more than 7%, Kelun Biotech (06990.HK) rising more than 6.5%, and WuXi AppTec (02359.HK) rising more than 5%.
13:16
Hong Kong stocks of innovative drugs strengthened in the afternoon, Rongchang Biopharma and China Biopharmaceutical rose by more than 15%
Hong Kong stocks with innovative drug concepts strengthened in the afternoon, with Rongchang Biopharma and China Biologic Products rising by more than 15%, Junshi Biosciences, Zhaoyan Pharmaceutical, BeiGene, and CStone Pharmaceuticals rising by more than 5%.
09:55
Hong Kong-listed biopharmaceutical stocks rose in early trading, with Zai Lab (09688.HK) up more than 8.5%, Kelun Biotech (06990.HK) up nearly 6%, BeiGene (06160.HK) up more than 4%, Rongchang Biopharmaceuticals (09995.HK), WuXi Biologics (02269.HK), InnoCare Pharma (09969.HK), and WuXi AppTec (02359.HK) all up more than 3%.
2025.06.04
16:37
FTSE Russell announced the results of the June 2025 quarterly review. Jiangsu Bank was included in the FTSE China A50 Index and Great Wall Motor was excluded; BeiGene, Yili Group, SAIC Group, SERES, Huichuan Technology and other stocks were included in the list of alternative stocks.
16:37
FTSE Russell announces June 2025 quarterly review results, FTSE China A50 Index includes Jiangsu Bank
FTSE Russell announced the results of the June 2025 quarterly review. Jiangsu Bank was included in the FTSE China A50 Index and Great Wall Motor was excluded; BeiGene, Yili Group, SAIC Group, SERES, Huichuan Technology and other stocks were included in the list of alternative stocks.
2025.05.29
16:38
The National Medical Products Administration conditionally approved the marketing of Zenedatumumab for injection
The National Medical Products Administration has conditionally approved the marketing of Zenidatuzumab for injection (trade name: Bhean) submitted by BeiGene (Suzhou) Biotechnology Co., Ltd. through the priority review and approval procedure. It is suitable for patients with unresectable locally advanced or metastatic biliary tract cancer with high HER2 expression (IHC3+) who have previously received systemic treatment. The launch of this product provides a new treatment option for related patients.
2025.05.27
21:26
BeiGene: Change of registered place of business to Switzerland
BeiGene announced that the company has changed its registered place from the Cayman Islands to Switzerland by continuing to register as a stock company in Switzerland on May 27, 2025. From the effective date of the continued registration, the company will apply the articles of association formulated in accordance with Swiss law, and the English name will be changed to BeOne Medicines Ltd., while the Chinese name will remain unchanged. Ernst & Young AG of Switzerland will serve as the company's Swiss statutory auditor until the date of the first annual general meeting of shareholders after the completion of the company's continued registration. Ernst & Young Hua Ming will continue to serve as the company's A-share audit agency.
2025.05.26
09:24
Many stocks in the Hong Kong biotechnology sector opened higher, with Zhaoyan Pharmaceutical (06127.HK) rising more than 4%, Tiger Pharmaceuticals (03347.HK) rising nearly 3%, Junshi Biosciences (01877.HK), BeiGene (06160.HK) and others following suit.
2025.05.22
09:37
The Hong Kong stock market's biopharmaceutical sector fell back and weakened, with Tiger Pharmaceuticals (03347.HK) falling nearly 3%, Rongchang Biopharma (09995.HK) falling more than 2%, BeiGene (06160.HK), WuXi AppTec (02359.HK) and others following suit.
2025.05.16
05:05
Hillhouse Capital's HHLR increased its Chinese assets in the first quarter and newly increased its holdings of multiple Chinese concept stocks
HHLR Advisors, an independent fund management platform under Hillhouse Capital that focuses on secondary market investment, announced its U.S. stock holdings as of the end of the first quarter of 2025. The 13F document shows that the total market value of HHLR's holdings in the first quarter increased from US$2.887 billion at the end of the previous quarter to US$3.539 billion, an increase of nearly 23%. Data shows that in the first quarter, HHLR continued to increase its allocation of Chinese assets, and newly entered and increased its holdings of nearly 20 Chinese concept stocks, including 10 companies such as Atour Group, Huazhu Group, Baidu, Yuchai International, Ideal Auto, Boss Direct Recruitment, and Ecarx Technology, as well as 8 companies such as Futu Holdings, Pinduoduo, NetEase, Beike, JD.com, Ctrip, and ZTO Express. As of the end of the first quarter of 2025, HHLR's top ten holdings were: Pinduoduo, Alibaba, Futu Holdings, BeiGene, NetEase, Beike, Legend Biotech, JD.com, Vipshop, and WNS HLDGS LTD, with Chinese concept stocks accounting for 9 seats. HHLR reduced its holdings in companies such as Alibaba and BeiGene in the first quarter.
2025.05.15
12:45
Hillhouse Capital reduces its stake in BeiGene. Industry insiders: The fund expires and LPs have a need for distribution. This is a normal exit
BeiGene issued an announcement stating that the company's shareholder HHLRFund, LP and its affiliated entities reduced their holdings of the company's overseas outstanding shares by 16 million shares on May 9, and their shareholding ratio dropped from 6.03% to 4.89%, and they are no longer shareholders holding more than 5% of the company's shares. It is worth noting that as of September 30, 2024, HHLRFund, LP and its affiliated entities held 10.31% of the shares. This means that in more than 7 months, Hillhouse's share reduction ratio was as high as 5.42 percentage points, and it sold more than half of its holdings. An industry insider told reporters that the investment period of a fund generally does not exceed 10 years. Hillhouse's reduction in holdings this time is mainly because it has invested in BeiGene for more than 10 years. The fund is now due and LP has a distribution demand. This is a normal exit of the fund. "For investment institutions, the business model is to invest in different targets, lock in profits and exit, and then look at new investments to make asset reallocations."
Load More
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
Weekly Highlights
Air India flight returns after takeoff due to technical issues

2025-06-16

Southbound funds made a large net purchase of 5.743 billion yuan today. In terms of Hong Kong Stock Connect (Shanghai), China Construction Bank and Meituan-W received net purchases of HK$1.108 billion and HK$493 million respectively; Xiaomi Group-W ranked first in net sales, with an amount of HK$1.489 billion; in terms of Hong Kong Stock Connect (Shenzhen), Meituan-W and Kangfang Biopharma received net purchases of HK$622 million and HK$206 million respectively; Xiaomi Group-W ranked first in net sales, with an amount of HK$391 million.

2025-06-16

Arm (ARM.O): We are better than Nvidia on a wider range of platforms.

2025-06-12

Lei Jun: Xiaomi Yu7 will be released at the end of June

2025-06-16

Putin: Russia will create unmanned system forces as a separate branch of the military

2025-06-13

ASIA TECH WIRE

Grasp technology trends

Download